产品
编 号：F756860
分子式：C55H87N15O22
分子量：1310.37
分子式：C55H87N15O22
分子量：1310.37
产品类型
规格
价格
是否有货
结构图
CAS No: 2919976-92-2
产品详情
生物活性：
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy.
体内研究：
CXJ-2 (150 μg/kg，腹腔注射，每日一次，持续 3 周)可显著减轻小鼠肝纤维化。CXJ-2 (0.1 mg/kg，皮下注射，单剂量)显示出良好的药代动力学特性。Animal Model:Male C57BL/6J mice (6-8 weeks, 20-24 g, CCl4-induced liver fibrosis model)
Dosage:150 μg/kg
Administration:IP, daily, for 3 weeks
Result:Significantly decreased the HYP (hydroxyproline) content in liver tissue. Decreased collagen deposition. Remarkably diminished hepatic fibrosis.
Animal Model:Sprague-Dawley rats
Dosage:0.1 mg/kg
Administration:SC, single dose (Pharmacokinetic Analysis)
Result:Showed favorable pharmacokinetic properties (Tmax=0.33 h, T1/2=0.46 h), and displayed enhanced clearance profiles. Displayed significantly higher serum stability with a half-life longer than 36 h.
体外研究：
CXJ-2 (10 μM , 24 h) 以剂量依赖性方式降低 LX2 细胞中的 α-SMA 表达。CXJ-2 (10 μM , 24 h) 表现出优异的抑制 LX2 细胞增殖的活性。
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy.
体内研究：
CXJ-2 (150 μg/kg，腹腔注射，每日一次，持续 3 周)可显著减轻小鼠肝纤维化。CXJ-2 (0.1 mg/kg，皮下注射，单剂量)显示出良好的药代动力学特性。Animal Model:Male C57BL/6J mice (6-8 weeks, 20-24 g, CCl4-induced liver fibrosis model)
Dosage:150 μg/kg
Administration:IP, daily, for 3 weeks
Result:Significantly decreased the HYP (hydroxyproline) content in liver tissue. Decreased collagen deposition. Remarkably diminished hepatic fibrosis.
Animal Model:Sprague-Dawley rats
Dosage:0.1 mg/kg
Administration:SC, single dose (Pharmacokinetic Analysis)
Result:Showed favorable pharmacokinetic properties (Tmax=0.33 h, T1/2=0.46 h), and displayed enhanced clearance profiles. Displayed significantly higher serum stability with a half-life longer than 36 h.
体外研究：
CXJ-2 (10 μM , 24 h) 以剂量依赖性方式降低 LX2 细胞中的 α-SMA 表达。CXJ-2 (10 μM , 24 h) 表现出优异的抑制 LX2 细胞增殖的活性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备